Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

24 Versus 48 Hours of First Generation or Second Generation Cephalosporin as Prophylaxis to Reduce Surgical Site Infection in Adult Cardiac Surgery Patients: a Randomized Controlled Trial

NCT04303390 is registered in ClinicalTrials.gov with Saud Al Babtain Cardiac Center as lead sponsor.

NCT NCT04303390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04303390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
24 Versus 48 Hours of First Generation or Second Generation Cephalosporin as Prophylaxis to Reduce Surgical Site Infection in Adult Cardiac Surgery Patients: a Randomized Controlled Trial
Lead sponsor
Saud Al Babtain Cardiac Center
Phase
Phase 4
Overall status
Completed
Start date
February 6, 2018
Completion date
May 31, 2022
Enrollment
568 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

surgical site infection